menu
    • menu

    Company profile for Enzyvant

    NEW Drugs in Dev: 2
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Enzyvant is a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases. Enzyvant’s lead asset is the investigational tissue-based regenerative therapy, RVT-802, for congenital athymia, an ultra-rare and life-threatening pediatric immunodeficiency. RVT-802 has been granted multiple regulatory designations, including the US Food and Drug Administration...
    Enzyvant is a biotechnology company dedicated to developing novel, transformative regenerative therapies for people with devastating rare diseases. Enzyvant’s lead asset is the investigational tissue-based regenerative therapy, RVT-802, for congenital athymia, an ultra-rare and life-threatening pediatric immunodeficiency. RVT-802 has been granted multiple regulatory designations, including the US Food and Drug Administration expedited designation as a Regenerative Medicine Advanced Therapy (RMAT). Enzyvant is part of Sumitovant Biopharma (wholly owned by Sumitomo Dainippon Pharma).

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    EnzyvantUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    55 Cambridge Parkway, Suite 102W Cambridge, MA 02142
    Telephone
    Telephone
    +1 833 369 9868
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://enzyvant.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/enzyvant/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/enzyvant

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Sumitomo Pharma tidies up 7 units into 1 combined U.S. entity
    Sumitomo Pharma tidies up 7 units into 1 combined U.S. entity

    03 Apr 2023

    // Annalee Armstrong FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/sumitomo-pharma-tidies-7-units-one-combined-us-entity-spring-cleaning

    Annalee Armstrong FIERCE BIOTECH
    03 Apr 2023
    Share Share
    Sumitovant subsidiaries Enzyvant and Altavant merge into combined company
    Sumitovant subsidiaries Enzyvant and Altavant merge into combined company

    06 Dec 2022

    // Tyler Patchen ENDPTS

    https://endpts.com/sumitovant-subsidiaries-enzyvant-and-altavant-merge-into-combined-company/

    Tyler Patchen ENDPTS
    06 Dec 2022
    Share Share
    Another new manufacturing site for NC; BioCentriq acquired by South Korean
    Another new manufacturing site for NC; BioCentriq acquired by South Korean

    22 Apr 2022

    // Josh Sullivan ENDPTS

    https://endpts.com/another-new-manufacturing-site-for-nc-biocentriq-acquired-by-south-korean-company/

    Josh Sullivan ENDPTS
    22 Apr 2022
    Share Share
    Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing
    Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing

    21 Apr 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/04/21/2426405/0/en/Enzyvant-Announces-Plans-to-Expand-Regenerative-Medicine-Manufacturing-Capabilities.html

    GLOBENEWSWIRE
    21 Apr 2022
    Share Share
    Enzyvant’s Path From CRL To FDA Approval For CMC Revamp
    Enzyvant’s Path From CRL To FDA Approval For CMC Revamp

    12 Jan 2022

    // B. Sandburg PHARMAINTELLIGENCE

    https://pink.pharmaintelligence.informa.com/PS145489/Enzyvants-Path-From-Complete-Response-Letter-To-FDA-Approval-For-Rethymic-Included-CMC-Revamp

    B. Sandburg PHARMAINTELLIGENCE
    12 Jan 2022
    Share Share
    FDA approves Enzyvant's regenerative tissue-based therapy
    FDA approves Enzyvant's regenerative tissue-based therapy

    11 Oct 2021

    // SEEKING ALPHA

    https://seekingalpha.com/pr/18506218-enzyvant-receives-fda-approval-for-rethymic-allogeneic-processed-thymus-tissue-agdc-one-time

    SEEKING ALPHA
    11 Oct 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search